PHRX — Pharmadrug Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- CA$1.57m
- CA$2.91m
Annual income statement for Pharmadrug, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS/A | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.611 | 0.684 | 0.007 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 0.253 | 0.182 | -0.002 | -0.002 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 5.66 | 4.35 | 2.8 | 2.41 | 14 |
Operating Profit | -5.05 | -3.67 | -2.8 | -2.41 | -14 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.98 | -5.9 | -4.28 | -3.25 | -14.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.54 | -5.43 | -4.28 | -3.06 | -13.3 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -6.29 | -5.15 | -5.63 | -8.88 | -13.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.29 | -5.15 | -5.63 | -8.88 | -13.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.631 | -0.258 | -0.085 | -0.061 | -0.09 |